We evaluated the effects of tranexamic acid (TA) administered before and after cardiopulmonary bypass (CPB) in a prospective, randomized, placebocontrolled, double-blind study of adult patients undergoing primary coronary artery bypass grafting surgery. Patients received placebo (n = 30) or TA 15 mg/ kg before CPB, followed by a TA infusion of 1 mg * kg-r . h-i for 5 h (n = 30) or TA 15 rng/ kg after CPB, followed by a TA infusion of 1 mg * kg * h ' for 5 h (n = 30). Demographic, medical, surgical, laboratory, mediastinal chest tube drainage (MCTD), hemoglobin loss, transfusion, and outcome data were collected. Allogenic blood product administration was tightly controlled. The demographic, medical, and surgical characteristics were similar in all three groups. The median postoperative MCTD and hemoglobin loss in the pre-CPB TA group (710 mL, 8.6 g) was significantly less (P < 0.001) compared with the control (1202 mL, 44.2 g) and post-CPB TA groups (1020 mL, 23.4 g). The percentage of patients who received no allogenic blood products was 27% for the pre-CPB TA group and 33% for the post-CPB TA group (not significant).
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We evaluated the effects of tranexamic acid (TA) administered before and after cardiopulmonary bypass (CPB) in a prospective, randomized, placebocontrolled, double-blind study of adult patients undergoing primary coronary artery bypass grafting surgery. Patients received placebo (n = 30) or TA 15 mg/ kg before CPB, followed by a TA infusion of 1 mg * kg-r . h-i for 5 h (n = 30) or TA 15 rng/ kg after CPB, followed by a TA infusion of 1 mg * kg * h ' for 5 h (n = 30). Demographic, medical, surgical, laboratory, mediastinal chest tube drainage (MCTD), hemoglobin loss, transfusion, and outcome data were collected. Allogenic blood product administration was tightly controlled. The demographic, medical, and surgical characteristics were similar in all three groups. The median postoperative MCTD and hemoglobin loss in the pre-CPB TA group (710 mL, 8.6 g) was significantly less (P < 0.001) compared with the control (1202 mL, 44.2 g) and post-CPB TA groups (1020 mL, 23.4 g). The percentage of patients who received no allogenic blood products was 27% for the pre-CPB TA group and 33% for the post-CPB TA group (not significant).
These percentages were significantly lower than those in the placebo group (66%, P < 0.001). The median number of allogenie blood products administered to the pre-CPB TA group (0 units) was significantly less compared with the control group (4.5 units). The thromboelastogram and fibrinogen split product levels in the pre-CPB TA group indicated better platelet function and less activation of the fibrinolytic system compared with the other two groups (P < 0.05). There were no intergroup differences in reoperation, myocardial infarction, stroke, infections, or death. These data support the use of pre-CPB TA to decrease patient exposure to postcardiopulmonary bypass allogenic blood products. Implications: In this randomized, placebo-controlled trial, we investigated the efficacy of tranexamic acid to decrease bleeding and blood transfusions after open-heart operations. Tranexamic acid administered before and during the operation was effective in decreasing both bleeding and transfusions. When tranexamic acid was administered immediately after the operation, it had a minor beneficial effect. (Anesth Analg 1997; 85:963-70) D iffuse microvascular bleeding (MVB) remains a common problem after cardiac procedures involving cardiopulmonary bypass (CPB). Diffuse MVB is a multifactorial coagulopathy in which the predominant factors are the loss of coagulation factors (l), acquired defects in platelet function (2,3), and fibrinolysis (4, 5) . In recent years, substantial data have accumulated, indicating that lysine analog antifibrinolytic drugs are effective in reducing bleeding after CPB (6-15), the percentage of patients administered allogenie blood products (8) (9) (10) 13) , and, rarely, the number of allogenic units transfused (13). The mechanism by which these drugs decrease bleeding is controversial but may involve decreases in plasmin generation and preservation of platelet function (16, 17) . Tranexamic acid (TA) is a synthetic antifibrinolytic drug that acts by inhibiting the lysine binding site on plasmin and plasminogen (l&19). TA reduces post-CPB blood loss when given before bypass (8) (9) (10) (13) (14) (15) . However, the efficacy of TA administered after CPB has not been well evaluated.
The studies that have evaluated the administration of TA administration after CPB were not randomized or did not compare post-CPB TA with a control (7,ll (7) showed decreases in mediastinal blood loss when TA was given before CPB rather than after CPB. To date, no randomized, placebo-controlled, prospective, blind study has compared the blood conservation effects of post-CPB administration of TA. It is similarly unclear whether TA administered before CI'B decreases the transfusion of allogenic blood products. A large (n = 419), nonrandomized, nonblind study by Rousou et al. (13) showed a decrease in the allogenic blood products transfused. Other studies have shown decreases in the percentage of patients administered allogenic blood products without a decrease in total number (&lo), or no decreases in the administration of allogenie blood products (11, 14, 15, 20) . This prospective, randomized, blind, placebo-controlled study was designed to investigate the optimal timing for the administration of tranexamic acid to decrease postcardiopulmonary blood loss and allogenic transfusions.
Methods
After receiving approval from the Brooke Army Medical Center Institutional Review Board, written, informed consent was obtained, and 91 patients scheduled for elective primary coronary revascularization were enrolled in this prospective, randomized, placebo-controlled trial. Inclusion criterion for patient enrollment included any patient scheduled for primary coronary artery bypass grafting surgery (CABG). Patients receiving heparin or aspirin were included in the study. Patients with a platelet count less than 100,000/mm3 or a coagulopathy, or those receiving thrombolytic therapy or warfarin were excluded from enrollment in this study.
Study Design
Patients were randomized using a computergenerated random number sequence to receive placebo (control), TA after termination of CPB (TA post-CPB), or TA before the initiation of and during CPB (TA pre-CPB). A priori power analysis based on MCTD and transfusion therapy in control patients from a previous study (21) indicated that a sample size of 90 Tranexamic Acid Infusion Protocol TA (Cyklocapron; Kabi Pharmaceutical, Piscataway, NJ) was purchased from the manufacturer. After randomization of the patients, the study infusions were delivered to the operating room on the morning of surgery and were identified either as Infusion 1, Infusion 2, Infusion 3, or Infusion 4. Infusion 1 was TA (15 mg/ kg) mixed in 50 mL of normal saline or placebo (50 mL normal saline) and was administered to the patient over 20 min after the induction of anesthesia and before sternotomy. Infusion 2 consisted of TA (500 mg) mixed in 250 mL of normal saline or placebo (250 mL normal saline). Infusion 2 was started after the completion of Infusion 1 and was infused at a standard rate of 0.5 mL * kg-i * h-r (1 mg * kg-' . h-l). After termination of CPB and reversal of heparin, Infusion 2 was stopped and Infusion 3 initiated. Infusion 3 consisted of TA (15 mg / kg) mixed in 50 mL of normal saline or placebo (50 mL normal saline) and was administered to the patient over 20 min. After completion of Infusion 3 the final infusion was started. Infusion 4 was identical to Infusion 2 and was administered at a rate of 0.5 mL * kg-' * h-' (1 mg * kg-' . h-l) for 5 h. Table 1 d' isp ays 1 a matrix that identifies the combination of the four infusions, which were administered to the patient groups during the study to accomplish administration of placebo, post-CPB TA, or pre-CPB TA.
Anesthetic Technique
All patients were premeditated with lorazepam l-2 mg orally and morphine sulphate 5-10 mg intramuscularly (IM) 1 h before presenting to the operating room. The anesthetic technique for the procedure consisted of 40-50 pg/kg of fentanyl, lo-15 mg of midazolam, and supplemental isoflurane as deemed clinically necessary by the attending anesthesiologist. Neuromuscular block was achieved and maintained with vecuronium or pancuronium.
Group
Infusion 1 
Cardiopulmona y Bypass Management
The CPB circuit consisted of a nonocclusive roller pump with a 40-F arterial filter, a membrane oxygenator (Maxima Plus; Medtronic Cardiopulmonary, Anaheim, CA), a cardiotomy reservoir, and polyvinyl tubing. The oxygenator was primed with lactated Ringer's solution (22), sodium bicarbonate (50 mEq), bovine heparin (10,000 units; Upjohn, Kalamazoo, MI), cephapirin
(1 g), mannitol (12 g), and 25% albumin (100 mL). Systemic anticoagulation was induced with 300 units/kg of bovine heparin injected via a central vein before aortic cannulation.
After the celiteactivated clotting time (ACT) (Hemocron 8000; International Technidyne
Corp., Edison, NJ) was documented to be greater than 400 s, CPB was performed with a normothermic flow rate of 4.5-5.0 L / min and a moderate hypothermic (28-30 C bladder) flow rate of 2.5-3.0 L/min. The celite ACT was measured every 30 min and maintained >480 s with supplemental heparin administration (5000 units) as needed. Myocardial protection was induced with 15 mL I kg of cold, high-potassium (20 mEq/L) 4:l blood to crystalloid cardioplegia administered through the aortic root after aortic occlusion. Subsequent blood to crystalloid cardioplegia (7.5 mL / kg) was administered retrograde and through the vein grafts every 20 min. After the termination of CPB, systemic heparinization was neutralized with protamine sulfate (Fujisawa USA, Inc., Deerfield, IL) based on an automated protamine titration (Hepcon HMA; Hemotec Inc, Englewood, CA). If the ACT exceeded 140 s 10 min after the calculated protamine dose, an additional 50 mg of protamine was administered, and the celite ACT and protamine titration were repeated to determine efficacy.
Transfusion Policies
The indication for allogenic red blood cell transfusions during CPB was a hemoglobin concentration <6 g/ dL. After the termination of CPB and the administration of the washed, concentrated (Electromedics, Englewood, CA) cellular contents of the CPB circuit, the indication for allogenic red blood cell transfusions was a hemoglobin <8 g/dL. In the operating room, blood components were administered based on the diagnosis of diffuse MVB. MVB was defined as diffuse bleeding with minimal to no clot formation after meticulous inspection of all anastomoses and the internal mammary artery bed for the etiology of bleeding. In the intensive care unit (ICU), blood components were administered for excessive MCTD in conjunction with laboratory testing. Excessive MCTD was defined as blood loss greater than 300 mL for any single hour or greater than 200 mL/h for two consecutive hours. Six units of platelets were administered for bleeding associated with a platelet count of less than lOO,OOO/ mm3. Two to four units of fresh frozen plasma were administered for bleeding associated with an increased prothrombin (>20 s) or activated partial thromboplastin time (>60 s) (1). Cryoprecipitate (10 units) was administered for excessive bleeding in conjunction with a fibrinogen level less than 100 mg/ dL. Surgical reexploration was undertaken if excessive bleeding was diagnosed with normal laboratory parameters.
Laboratory Testing
Preoperative laboratory tests included complete blood cell count (CBC), fibrinogen level, fibrinogen split products (FSPs), prothrombin time (PT), activated partial thromboplastin time (aPTT), and template bleeding time. After the termination of CPB and neutralization of the residual heparin with protamine, a laboratory fibrinogen level, PT, aPTT, and a thromboelastogram (TEG) (Thrombelastogram; Haemoscope, Morton Grove, IL) were performed in the operating room. On arrival in the ICU, a CBC, fibrinogen level, FSPs, PT, aPTT, and a TEG were again performed. A CBC, PT, and aPTT were performed every 6 h for the first 24 h after arrival in the ICU.
Outcome Measures and Complications
Blood loss from the mediastinal chest tubes was measured hourly for the first 24 h in the ICU. Excessive 24-h MCTD was defined as losses greater than 1 L (12). At the end of 24 h, the MCTD was emptied from the reservoir and thoroughly mixed, a sample was sent to the laboratory for a hemoglobin determination. The time of administration of all allogenic blood products was recorded. The use of an intraortic balloon pump was recorded. A Q wave myocardial infarction was defined as a new Q wave greater than 40 ms duration on an electrocardiogram obtained on the morning of the second postoperative day. The occurrence of a new computed tomographic focal ischemic brain lesion associated with focal neurologic deficits (stroke) or death for any reason within 30 days of surgery was recorded. Mediastinal or systemic infections that occurred within 30 days were also recorded.
Statistical Analysis
Descriptive statistics for the groups are presented as means + SD, median with quartile ranges, or as group percentages. Differences among groups were assessed using a one-way analysis of variance (ANOVA) technique with a post hoc Student-Newman-Keuls multiple range test to detect intergroup differences. Nonparametric data were analyzed using the Kruskal-Wallis (KW) ANOVA on ranks with Dunn's method for post hoc comparison of multiple groups. 2 analysis was CARDIOVASCULAR ANESTHESIA TRANSFUSIONS 1997; 85:963-70 used to determine differences in proportions and categorical variables. A two-tailed intergroup P value < 0.05 after the correction for multiple comparisons was considered statistically significant.
Results
Patient demographic, medical, and surgical characteristics are shown in Table 2 . There were no intergroup differences in any of these characteristics. The hematologic, TEG, and coagulation variables are listed in Table 3 . There were no differences among the groups in the laboratory parameters measured preoperatively. Intraoperative hemoglobin measurements at the termination of CPB revealed equivalent levels of hemodilution among the groups. ACT, PT, and aPTT measurements after protamine administration were similar among the groups. The TEG values obtained after protamine administration and heparin neutralization showed significant differences in the maximum amplitude (MA) of the tracing and the whole blood clot lysis index (WBCLI). The MA of the pre-CPB TA group was significantly larger than that of the other two groups (P = 0.017, ANOVA). Fibrinolysis, as measured by the TEG WBCLI, was less in the pre-CPB TA group (P = 0.023, ANOVA) compared with the control group, but was not significantly different from the WBCLI of the post-CPB TA group. After arrival in the ICU, there were no differences in the measured laboratory values, with the exception of the FSPs (P < 0.001). A lower percentage (3%) of the pre-CPB TA group had FSPs detectable over a concentration of 10 pg/mL. The other groups exhibited a 50%-60% incidence of excessive FSPs after CPB. Heparin rebound was not detected in the ICU.
The volume of MCTD and the associated hemoglobin content during the initial 24 h in the ICU are depicted in Figure 1 . The measured drainage and hemoglobin loss in the pre-CPB TA group was significantly less compared with the other groups (P < 0.001, KW); however, there were no differences between the placebo and post-CPB groups. All groups received a similar volume of washed, concentrated residual CPB circuit volume (733 + 265, 739 + 248, 770 ? 220 mL, P = 0.79, ANOVA). Figure 2 details the total allogenic transfusions for all blood products. The median number of blood products transfused (0 units each group) and the percentage of patients (27% vs 33%) receiving any blood products were not significantly different for the pre-and post-CPB TA groups. A significantly higher percentage of patients (66%) received blood products in the control group compared with the other groups (P < 0.05). However, the number of units transfused was significantly lower only in the pre-CPB group (P = 0.005, KW). The differences in allogenic unit exposures for the pre-CPB TA group were accounted for by significant differences in the transfusion of platelets (P = 0.008, KW), fresh-frozen plasma (P = 0.044, KW), and cryoprecipitate (P = 0.008, KW). Values are expressed as mean (SD). There were no differences in the preoperative laboratory studies. The intraoperative postcardiopulmonary bypass tests indicated that the platelet-fibrinogen interaction as indicated by the maximum amplitude of the thromboelastogram was significantly greater in the pre-CPB TA group and that the activation of the fibrinolytic system as indicated by the whole blood clot lysis index was less. The decreased activation of fibrinolytic system was confirmed by the low percentage of patients with fibrinogen split products greater than 10 &mL in the pre-CPB TA group. TA = tranexamic acid, Cl'B = cardiopulmonary bypass, WBCLI = whole blood clot lysis index. * Significantly different compared with placebo and post-CPB TA groups. t Significantly different compared with placebo. n = 30 for each group.
There were no differences in the number of units of packed red cells transfused to any group (P = 0.128, KW). However, the calculated power of that analysis was only 0.259.
Outcome
measurements are recorded in Table 4 .
Two patients required reexploration for excessive MCTD. A surgical bleeding site could not be found in the control group patient. However, surgical bleeding was identified and corrected in one post-CPB TA group patient. Consequently, that patient was excluded from data analysis, and the patient was replaced in the study. No strokes or transmural myocardial infarctions manifested by new Q waves on the postoperative electrocardiograms were detected. There was one death during the course of the study. This death occurred in the post-CPB TA group 6 days postoperatively and was secondary to urosepsis.
The only significant variable among the three groups was the difference in the number of patients with excessive MCTD (>lOOO mL/24 h). The control group had 20 patients and the post-CPB TA group had 15 patients with excessive drainage. The pre-CPB TA group had only 4 patients with MCTD >lOOO mL in the first 24 h.
Discussion
Coagulopathies have long been known to occur during cardiac surgery. Contact of blood with the large artificial surface of the CPB circuit leads to the activation of the contact phase of coagulation. Factor XII binds to the negatively charged surfaces of the CPB circuit tubing and initiates the intrinsic coagulation cascade. In addition, the fibrinolytic system is also activated, and plasmin is generated. This process consumes clotting factors, dissolves the fibrin clot (fibrinolysis), and predisposes the patient to bleeding. Furthermore, CPB induces platelet dysfunction. Although the exact mechanisms are controversial, impaired platelet adhesion and aggregation results from platelet degranulation, defects in platelet surface proteins GPIb and GPIIb /IIIa, plasmin-mediated platelet effects, and, possibly, from other unknown defects extrinsic to the platelet. and hemoglobin (Hb) content of the MCTD in the three study groups. The group that received tranexamic acid (TA) before cardiopulmonary bypass (CPB) had significantly less MCTD and Hb content compared with the other groups. The data are presented as the median with the 25th and 75th quartiles, the 5th and 95th percentiles, and the outliers for each group. to each the patient who received tranexamic acid (TA) before cardiopulmonary bypass (CPB) was significantly lower than in the other two groups. The data are presented as the median with the 25th and 75th quartiles, the 5th and 95th percentiles, and the outliers for each group. The percentage of patients who received any allogenic blood products was similar in both TA groups but significantly less than the control group.
TA is a synthetic antifibrinolytic that prevents the plasmin-mediated conversion of fibrinogen to FDPs. TA works by competitively inhibiting the lysine binding sites on plasmin(ogen) and fibrin(ogen) (l&19). By decreasing the generation of plasmin, TA can decrease plasmin-mediated platelet dysfunction (16, 17) . TA functions similarly to another antifibrinolytic, Eaminocaproic acid (EACA), although it has a longer half-life and stronger plasminogen binding than EACA (18). Despite several earlier reports that showed beneficial hemostatic effects from the administration of EACA after the termination of CPB (6,12), most investigations have since found decreases in MCTD with minimal impact on transfusions when antifibrinolytics are given before CPB (S-10,20) . However, most of the studies involving TA have been uncontrolled, did not study patients at risk of coagulopathies, did not control for transfusion practices, or had insufficient power to conclude definite benefits from prophylactic administration. Our patients were ideal candidates for pharmacologic (12) interventions to decrease bleeding because of their history of prolonged CPB times and excessive MCTD experienced at our institution (22). In addition, specific transfusion criteria were applied to minimize subjective administration of allogenic blood products in the postoperative period.
Blood Loss
The results of this study indicate that TA administration before CPB is effective in decreasing MCTD and mediastinal hemoglobin loss. Administration of TA after heparin neutralization had no significant effects in mitigating MCTD or hemoglobin loss. The postoperative MCTD in the group of patients that received TA before the initiation of CPB was 30%-40% less compared with the other two groups. In addition to decreasing MCTD, the hemoglobin loss in the pre-CPB TA group was 25% of that in the other groups. These findings are consistent with previous studies (8) (9) (10) (11) (13) (14) (15) ) that have reported a 30%-70% decrease in MCTD when TA is given before CPB. Blauhut and colleagues (20) found that prophylactic TA was not effective in decreasing MCTD after CPB. However, the mean blood loss of 450 mL in the control group and the CPB time of 75 minutes indicates that study population was different from the patients in our study. Although post-CPB administration of TA was not as effective as pre-CPB administration, there seems to be a nonsignificant trend in the decrease of MCTD and hemoglobin loss in the patients administered TA after CPB compared with the control group. However, the magnitude of the difference in the mean MCTD, the 1997;85:963-70 CARDIOVASCULAR ANESTHESIA BROWN ET AL.
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TRANEXAMIC ACID REDUCES POST-CPB TRANSFUSIONS variability of the MCTD, and the group sizes indicate that there was insufficient power to detect a beneficial effect of post-CPB TA. One previous nonblind, nonrandomized, retrospective evaluation determined that post-CPB TA was marginally effective in decreasing MCTD (11) . In that study, Ovrum et al. (11) administered TA as a 40-mg/ kg single bolus without an infusion. The l&hour bleeding was statistically less in the TA group (565 vs 656 mL). Our results are similar to the only other randomized, blind study that compared the pre-CPB versus post-CPB administration of TA. In a small cohort of 17 patients, Soslau et al. (7) found a more than 50% decrease in MCTD when TA was given pre-CPB versus post-CPB.
Allogenic Transfusions
Although MCTD is a variable routinely included in studies evaluating blood conservation measures, it is only a surrogate marker for allogenic transfusions and transfusion-related complications (12, 21) . In this evaluation, pre-CPB TA not only displayed a salutary effect in decreasing MCTD and hemoglobin loss, but there were also significant decreases in the percentage (27% vs 66%) of patients administered allogenic blood products and the number of units to which the patients were exposed. These findings have been observed in only one previous TA study. Rousou et al. (13) evaluated prophylactic TA versus retrospective controls and found a significant decrease in MCTD and allogenic transfusions in the TA-treated patients. Although the study did control for transfusion practices and evaluated patients at risk of postoperative bleeding, it was not blinded, nonrandomized, or retrospectively controlled. The failure of the other studies to observe an effect in reducing allogenic transfusions may be related either to insufficient sample size or to shorter CPB times, and, thus, low relative risk for, coagulation disturbances in their patient populations (8) (9) (10) 14, 15) .
In this evaluation, there was no benefit in decreasing total blood product exposure in the patients administered TA after CPB. However, the finding of decreases in the percentage of patients transfused compared with the control group is similar to that of previous prophylactic TA administration studies (8-10). The previous evaluations of post-CPB administration of TA have shown no benefits in regard to allegenie transfusions (7,ll).
Coagulation
During the first 60 minutes of CPB, there is a profound increase in total plasminogen activator levels, which return to baseline around 24 hours after CPB (23). There is an almost parallel decrease in plasminogen activator inhibitor activity which normalizes several hours after CPB (24). Together, the tissue plasminogen activator increase and plasminogen activator inhibitor decrease promote a state of fibrinolysis.
Platelet function is also considerably affected by CPB. The etiology of platelet dysfunction is multifactorial and has been attributed to loss of (Y and dense granules and the secretion of p-thromboglobin and ADP (2,25). Subsequent to platelet degranulation, platelet-fibrinogen binding is compromised (26, 27) . Because of the long CPB times in this investigation, there was activation of the fibrinolytic system and deterioration of platelet function. Our results indicate that compared with placebo and post-CPB TA, pre-CPB TA inhibited fibrinolysis, as evidenced by fewer patients with positive FSP measurements (>lO pg/mL) and a greater TEG WB-CLI. The decrease in fibrinolysis conferred by TA has been observed in previous studies (7, 8, 20) .
Although the mechanism of platelet dysfunction is multifactorial, plasmin has been implicated as a major factor in promoting the degradation of post-CPB platelet function (16, 17) . Few studies have specifically evaluated the platelet preservation effects of TA. In a study comparing pre-CPB TA versus post-CPB TA, Soslau et al. (7) showed that pre-CPB TA preserved platelet function and hemostasis by blocking plasmininduced partial platelet activation during CPB. In the study by Blauhut et al. (20) , post-CPB ADP platelet aggregation was preserved by TA to the same degree as aprotinin. In this evaluation, the TEG to MA ratio was used as an indicator of platelet function. Although the TEG is a different method than the ADP aggregation used in previous studies (7, 20) , both methods evaluate GIIb / IIIa receptor function and, thus, platelet-fibrinogen interaction (28). The TEG to MA ratio changes observed in this investigation are consistent with the decrements in platelet function more directly measured by other investigators.
We believe that the improved coagulation status of the patients administered TA before CPB was probably secondary to the inhibition of plasmin generation or plasmin itself (18), and to decreases in plasminmediated platelet dysfunction (16, 17) .
Limitations
There are three major limitations of this study. The first is that definitive laboratory evidence of a proposed mechanism for TA preservation of platelet function was not evaluated. The TEG provides useful information but could not precisely quantify the improved platelet function in the pre-CPB TA group. The second limitation is that the study is not sufficiently powered to determine differences in lowoccurrence complications, such as infections, stroke, or graft occlusion. The third major limitation is that the study size is too small to detect definitive beneficial effects from post-CPB TA administration. Although TRANSFUSIONS 1997; 85:963-70 fewer patients in that group received allogenic transfusion, the total units transfused and laboratory studies do not support a major beneficial effect.
Conclusions
This study has convincingly shown that pre-CPB TA has profound beneficial hemostatic and blood conservation effects in cardiac surgery in patients at risk of postoperative bleeding. TA exerts an optimal hemostatic effect when given before CPB. It significantly inhibits fibrinolysis and platelet dysfunction compared with placebo, resulting in less 24hour blood loss and blood product administration.
The beneficial effect of post-CPB TA is less clear. Post-CPB TA did result in a decrease in the percentage of patients transfused allogenic blood products, but it did not decrease the number of units transfused.
